Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Dermapharm Holding SE

Healthcare US DMPHF

53.0USD
13.44(33.97%)

Last update at 2026-06-22T13:41:00Z

Day Range

53.0053.00
LowHigh

52 Week Range

37.5848.60
LowHigh

Fundamentals

  • Previous Close 39.56
  • Market Cap2129.91M
  • Volume100
  • P/E Ratio17.90
  • Dividend Yield2.22%
  • EBITDA264.74M
  • Revenue TTM1178.39M
  • Revenue Per Share TTM21.89
  • Gross Profit TTM 765.74M
  • Diluted EPS TTM2.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 183.44M 172.00M 106.00M 216.30M 292.98M
Minority interest - 2.05M 1.83M 1.62M 0.68M
Net income 132.36M 113.79M 62.37M 134.24M 209.58M
Selling general administrative - 13.56M 20.24M 16.10M 13.07M
Selling and marketing expenses - 74.81M 75.04M 50.65M 52.81M
Gross profit 391.56M 767.07M 704.14M 660.83M 620.69M
Reconciled depreciation - 86.78M 101.77M 94.91M 55.16M
Ebit 221.66M 230.41M 160.97M 228.63M 301.81M
Ebitda 314.19M 320.91M 262.74M 323.54M 356.97M
Depreciation and amortization 92.53M 90.50M 101.77M 94.91M 55.16M
Non operating income net other - - - - -
Operating income 221.66M 216.93M 182.89M 243.69M 298.47M
Other operating expenses 942.88M 963.83M 967.85M 782.73M 655.87M
Interest expense 52.64M 58.41M 54.97M 14.84M 8.84M
Tax provision - 60.27M 45.46M 83.68M 84.07M
Interest income - 13.99M 2.49M 0.33M 4.02M
Net interest income - -46.44800M -69.73400M -13.84600M -5.81400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 52.14M 60.27M 45.46M 83.68M 84.07M
Total revenue 1164.54M 1180.77M 1150.74M 1024.78M 942.91M
Total operating expenses 169.90M 550.14M 521.25M 418.78M 333.65M
Cost of revenue 772.98M 413.70M 446.60M 363.94M 322.22M
Total other income expense net -38.22368M -44.92800M -76.89700M -27.39000M -5.49200M
Discontinued operations - - - - -
Net income from continuing ops - 111.74M 60.53M 132.62M 208.90M
Net income applicable to common shares - - - 134.24M 209.58M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2204.00M 2080.02M 2160.67M 1412.84M 1406.97M
Intangible assets 480.26M 512.31M 544.86M 305.04M 294.84M
Earning assets - - - - -
Other current assets 49.41M 26.93M 54.79M 22.02M 39.93M
Total liab 1502.43M 1471.72M 1615.62M 880.34M 907.13M
Total stockholder equity 694.12M 604.42M 539.21M 531.59M 497.32M
Deferred long term liab - - - 92.92M 77.72M
Other current liab 116.02M 74.78M 108.66M -109.28500M -58.87400M
Common stock 53.82M 53.84M 53.84M 53.84M 53.84M
Capital stock - 53.84M 53.84M 53.84M 53.84M
Retained earnings 515.72M 433.19M 367.22M 355.36M 337.95M
Other liab - - - - 176.80M
Good will 586.84M 576.38M 578.52M 271.32M 264.73M
Other assets - - 0.00100M -0.00100M 127.99M
Cash 203.33M 121.19M 158.72M 149.92M 160.32M
Cash and equivalents - - - - -
Total current liabilities 342.80M 326.92M 394.49M 217.79M 155.61M
Current deferred revenue 1.22M - 0.94M 155.34M 96.61M
Net debt 848.56M 858.42M 921.66M 366.53M 419.98M
Short term debt 129.33M 89.94M 116.43M 4.89M 5.58M
Short long term debt - 84.81M 111.43M 1.87M 2.38M
Short long term debt total 1051.90M 979.61M 1080.39M 516.45M 580.30M
Other stockholder equity 100.75M 117.39M 0.00000M 0.00000M 0.00000M
Property plant equipment - - - - 222.29M
Total current assets 702.66M 593.50M 630.50M 533.95M 519.22M
Long term investments - - - - -
Net tangible assets - - - 48.15M 15.46M
Short term investments - 0.51M 0.82M 11.44M 11.74M
Net receivables 121.33M 105.00M 95.41M 100.15M 76.08M
Long term debt - 877.33M 950.71M 501.85M 565.71M
Inventory 328.59M 339.86M 317.41M 251.82M 240.53M
Accounts payable 96.23M 94.78M 86.64M 56.10M 52.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 23.82M 117.39M 118.14M 122.39M 105.52M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.62M 0.51M 103.93M 0.00100M 11.74M
Deferred long term asset charges - - - - -
Non current assets total 1501.33M 1486.52M 1530.18M 878.89M 887.75M
Capital lease obligations - 17.47M 18.25M 12.73M 12.21M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -29.61400M -415.43200M -99.00800M -48.25300M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -109.98879M -29.61400M -415.43200M -99.00800M -129.34700M
Net borrowings - 111.17M 715.00M 469.95M -25.90900M
Total cash from financing activities 13.32M -209.16900M 204.54M -199.76800M -80.97900M
Change to operating activities - - - -4.13800M -46.27100M
Net income 132.36M 172.00M 62.37M 216.30M 292.98M
Change in cash 96.45M -37.44000M 7.70M -10.39500M 41.11M
Begin period cash flow 106.88M 158.72M 151.02M 161.41M 120.30M
End period cash flow 203.33M 121.28M 158.72M 151.02M 161.41M
Total cash from operating activities 181.44M 201.38M 219.42M 288.53M 250.37M
Issuance of capital stock - - - - -
Depreciation 92.53M 86.78M 101.77M 94.91M 55.16M
Other cashflows from investing activities -33.08760M 8.32M 7.56M 5.18M 0.10M
Dividends paid 48.44M 47.38M 56.53M 116.83M 47.38M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -7.64314M -60.38200M -39.73100M 453.99M -2.10200M
Change to netincome - - - 107.00M 41.80M
Capital expenditures 42.10M 38.24M 41.54M 39.01M 61.20M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.80M -18.05600M 9.04M -4.13800M -46.27100M
Stock based compensation - - - - -
Other non cash items -48.24792M -39.35600M 46.24M -18.53500M -51.49700M
Free cash flow 139.34M 163.14M 177.88M 249.52M 189.16M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DMPHF
Dermapharm Holding SE		 13.44 33.97% 53.00 17.90 14.33 1.81 2.90 2.78 7.89
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

Dermapharm Holding SE

Lil-Dagover-Ring 7, Grünwald, Germany, 82031

Key Executives

Name Title Year Born
Dr. Hans-Georg Feldmeier CEO & Chairman of the Management Board NA
Mr. Christof Dreibholz CFO, Chief Compliance Officer & Member of Management Board 1968
Dr. Andreas Eberhorn Chief Marketing Officer & Member of Management Board 1976
Ms. Britta Hamberger Head of Investor Relations & Corporate Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.